Our results suggest that the continuously active HER2 downstream signaling pathways might be one of the mechanisms resulting in relatively lower sensitivity of trastuzumab in HER2-positive gastric cancer than breast cancer (Fig. 1). The gene discussed is ERBB2; the disease is breast carcinoma.